NeuroPace (NPCE)
(Delayed Data from NSDQ)
$7.97 USD
-4.63 (-36.75%)
Updated May 9, 2024 04:00 PM ET
After-Market: $7.98 +0.01 (0.13%) 6:20 PM ET
4-Sell of 5 4
F Value A Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$7.97 USD
-4.63 (-36.75%)
Updated May 9, 2024 04:00 PM ET
After-Market: $7.98 +0.01 (0.13%) 6:20 PM ET
4-Sell of 5 4
F Value A Growth A Momentum B VGM
Zacks News
Globus Medical (GMED) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Globus Medical (GMED) delivered earnings and revenue surprises of 30.91% and 3.41%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Thermo Fisher Scientific (TMO) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Thermo Fisher (TMO) delivered earnings and revenue surprises of 1.62% and 1.35%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
RxSight, Inc. (RXST) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
RxSight, Inc. (RXST) delivered earnings and revenue surprises of 12.86% and 19.46%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Alphatec (ATEC) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Alphatec (ATEC) delivered earnings and revenue surprises of -9.38% and 3.18%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Accuray (ARAY) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Accuray (ARAY) delivered earnings and revenue surprises of -500% and 8.20%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Pulse Biosciences, Inc (PLSE) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Pulse Biosciences, Inc (PLSE) delivered earnings and revenue surprises of 0% and 52.17%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
908 Devices Inc. (MASS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
908 Devices Inc. (MASS) delivered earnings and revenue surprises of 0% and 2.93%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Abiomed (ABMD) Q1 Earnings Top Estimates
by Zacks Equity Research
Abiomed (ABMD) delivered earnings and revenue surprises of 15.74% and 0.42%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Pulse Biosciences, Inc (PLSE) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Pulse Biosciences, Inc (PLSE) delivered earnings and revenue surprises of 5.88% and 36.57%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Shockwave Medical (SWAV) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Shockwave Medical (SWAV) delivered earnings and revenue surprises of 105.26% and 5.74%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
LivaNova (LIVN) Lags Q1 Earnings Estimates
by Zacks Equity Research
LivaNova (LIVN) delivered earnings and revenue surprises of -7.69% and 3.09%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Pfizer (PFE) Q1 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Pfizer (PFE) delivered earnings and revenue surprises of -2.41% and 3.14%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Meridian Bioscience and NeuroPace have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Meridian Bioscience and NeuroPace have been highlighted as Zacks Bull and Bear of the Day.
Bear of the Day: NeuroPace (NPCE)
by Kevin Cook
EPS estimates get slashed 50% but sales still expected to grow for this innovative epilepsy device